Shuaiying Cui | Profiles RNS

Shuaiying Cui, PhD

Assistant Professor

Boston University School of Medicine

Dept of Medicine

Hematology & Medical Oncology

PhD, University of Science and Technology of China

Websites

Cui Lab-Our mission is to understand the basic mechanisms of hematopoiesis and to develop novel therapies for blood disorders and malignancies at genetic and molecular levels.

ORCID : 0000-0001-9104-8517

Dr. Cui's research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation and demethylation. Such agents can be applied to the treatment of the patients with hematologic disorders such as sickle cell disease and beta-thalassemia, as well as acute myeloid leukemia (Blood cancer), which arise from congenital defects in genome. The findings from these preclinical studies could also help to establish therapeutic indications in other hematological malignancies.

Member
Boston University
Center of Excellence in Sickle Cell Disease

2019-2022 Doris Duke Charitable Foundation: Sickle Cell Disease/Advancing Cures Award

2017-2018 American Society of Hematology: Scholar Awards

2017-2018 Pfizer: ASPIRE US Sickle Cell Disease Competitive Research Awards

2013-2017 American Heart Association: Award for National Scientist Development Grant

BMC Research

Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis for sickle…
09/01/2019 - 08/31/2022 (PI)
Duke Charitable Foundation

American Society of Hematology (ASH) Junior Faculty Award in Basic/Translational research
07/01/2017 - 06/30/2019 (PI)
American Society of Hematology

Regulating transcriptional co-activator PGC-1a for the treatment of sickle cell disease
05/12/2017 - 06/30/2018 (PI)
Pfizer, Inc

LSD1 Inhibition for the treatment of beta-globin disorders
07/01/2016 - 06/30/2018 (PI)
American Heart Assoc

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Le CQ, Myers G, Habara A, Jearawiriyapaisarn N, Murphy GJ, Chui DHK, Steinberg MH, Engel JD, Cui S. Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. Blood. 2019 05 30; 133(22):2455-2459.View Related Profiles.

Le, Cuong
Murphy, George
Steinberg, Martin
Cui, Shuaiying

PMID: 30992270

Tang B, Wang S, Wang SG, Wang HJ, Zhang JY, Cui SY. Invertebrate Trehalose-6-Phosphate Synthase Gene: Genetic Architecture, Biochemistry, Physiological Function, and Potential Applications. Front Physiol. 2018; 9:30. PMID: 29445344; DOI: 10.3389/fphys.2018.00030;

Morrison TA, Wilcox I, Luo HY, Farrell JJ, Kurita R, Nakamura Y, Murphy GJ, Cui S, Steinberg MH, Chui DHK. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis. 2018 03; 69:1-9.View Related Profiles.

Chui, David
Murphy, George
Luo, Hong
Steinberg, Martin
Cui, Shuaiying
Morrison, Tasha

PMID: 29227829

de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80.View Related Profiles.

Lerner, Adam
Cui, Shuaiying

PMID: 28867658

Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol. 2017 06; 50:46-52. PMID: 28238805; DOI: 10.1016/j.exphem.2017.02.003;

Cui S, Engel JD. Reactivation of Fetal Hemoglobin for Treating ß-Thalassemia and Sickle Cell Disease. Adv Exp Med Biol. 2017; 1013:177-202. PMID: 29127681; DOI: 10.1007/978-1-4939-7299-9_7;

Ibanez V, Vaitkus K, Rivers A, Molokie R, Cui S, Engel JD, DeSimone J, Lavelle D. Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons. Blood. 2017 01 12; 129(2):260-263. PMID: 27908882; DOI: 10.1182/blood-2016-10-746727;

Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan; 92(1):E10-E11.View Related Profiles.

Steinberg, Martin
Cui, Shuaiying
Dai, Yan

PMID: 27766663; DOI: 10.1002/ajh.24590;

Rivers A, Vaitkus K, Ibanez V, Ruiz MA, Jagadeeswaran R, Saunthararajah Y, Cui S, Engel JD, DeSimone J, Lavelle D. The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis). Haematologica. 2016 Jun; 101(6):688-97. PMID: 26858356; PMCID: PMC5013966; DOI: 10.3324/haematol.2015.140749;

White JC, Pawar A, Fu G, Cui S, Tavernier F, Hamid M, Harro D, Giacherio D, Campbell AD, Hines PC. TR2/TR4 overexpression in a humanized sickle cell disease mouse model decreases RBC adhesion to VCAM-1. Blood Cells Mol Dis. 2015 Dec; 55(4):316-7. PMID: 26460253; DOI: 10.1016/j.bcmd.2015.07.003;

Showing 10 of 22 results. Show More

Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, Campbell A, Harro D, Iwase S, Trievel RC, Rivers A, DeSimone J, Lavelle D, Saunthararajah Y, Engel JD. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood. 2015 Jul 16; 126(3):386-96. PMID: 26031919; PMCID: PMC4504950; DOI: 10.1182/blood-2015-02-626259;

Cui S, Tanabe O, Sierant M, Shi L, Campbell A, Lim KC, Engel JD. Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic ß-type globin genes. Blood. 2015 Feb 26; 125(9):1477-87. PMID: 25561507; PMCID: PMC4342359; DOI: 10.1182/blood-2014-10-605022;

Shi L, Sierant MC, Gurdziel K, Zhu F, Cui S, Kolodziej KE, Strouboulis J, Guan Y, Tanabe O, Lim KC, Engel JD. Biased, non-equivalent gene-proximal and -distal binding motifs of orphan nuclear receptor TR4 in primary human erythroid cells. PLoS Genet. 2014 May; 10(5):e1004339. PMID: 24811540; PMCID: PMC4014424; DOI: 10.1371/journal.pgen.1004339;

Shi L, Lin YH, Sierant MC, Zhu F, Cui S, Guan Y, Sartor MA, Tanabe O, Lim KC, Engel JD. Developmental transcriptome analysis of human erythropoiesis. Hum Mol Genet. 2014 Sep 01; 23(17):4528-42. PMID: 24781209; PMCID: PMC4119405; DOI: 10.1093/hmg/ddu167;

Cui S, Tanabe O, Lim KC, Xu HE, Zhou XE, Lin JD, Shi L, Schmidt L, Campbell A, Shimizu R, Yamamoto M, Engel JD. PGC-1 coactivator activity is required for murine erythropoiesis. Mol Cell Biol. 2014 Jun; 34(11):1956-65. PMID: 24662048; PMCID: PMC4019057; DOI: 10.1128/MCB.00247-14;

Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med. 2013 Mar; 19(3):291-4. PMID: 23416702; DOI: 10.1038/nm.3101;

Campbell AD, Cui S, Shi L, Urbonya R, Mathias A, Bradley K, Bonsu KO, Douglas RR, Halford B, Schmidt L, Harro D, Giacherio D, Tanimoto K, Tanabe O, Engel JD. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18808-13. PMID: 22042865; PMCID: PMC3219144; DOI: 10.1073/pnas.1104964108;

Cui S, Kolodziej KE, Obara N, Amaral-Psarris A, Demmers J, Shi L, Engel JD, Grosveld F, Strouboulis J, Tanabe O. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic ß-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol. 2011 Aug; 31(16):3298-311. PMID: 21670149; PMCID: PMC3147791; DOI: 10.1128/MCB.05310-11;

Zhang Y, Sandy AR, Wang J, Radojcic V, Shan GT, Tran IT, Friedman A, Kato K, He S, Cui S, Hexner E, Frank DM, Emerson SG, Pear WS, Maillard I. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood. 2011 Jan 06; 117(1):299-308. PMID: 20870902; PMCID: PMC3037751; DOI: 10.1182/blood-2010-03-271940;

Kato K, Cui S, Kuick R, Mineishi S, Hexner E, Ferrara JL, Emerson SG, Zhang Y. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant. 2010 Jun; 16(6):751-71. PMID: 20116439; PMCID: PMC2913321; DOI: 10.1016/j.bbmt.2010.01.012;

Cui SY, Zhang WQ, Xu WH. Spatial and temporal expression of N-ethylmaleimide-sensitive factor gene in the nervous system of the cotton bollworm, Helicoverpa armigera. Insect Biochem Mol Biol. 2006 Jul; 36(7):603-9. PMID: 16835026; DOI: 10.1016/j.ibmb.2006.05.004;

Cui SY, Xu WH. Molecular characterization and functional distribution of N-ethylmaleimide-sensitive factor in Helicoverpa armigera. Peptides. 2006 Jun; 27(6):1226-34. PMID: 16386334; DOI: 10.1016/j.peptides.2005.11.011;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 22 publications over 11 distinct years, with a maximum of 4 publications in 2017

Bar chart showing 22 publications over 11 distinct years, with a maximum of 4 publications in 2017

Year	Publications
2005	1
2006	1
2010	2
2011	2
2013	1
2014	3
2015	3
2016	3
2017	4
2018	1
2019	1

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Fetal Hemoglobin
Sickle Cell Disease
Sickle Cell Anemia
LSD1
PGC-1
Thalassemia

Available to Mentor as: (Review Mentor Role Definitions):